Preclinical Considerations for Development of Antibody-Based Therapeutics in Oncology
作者： Gregory Landes , Kathleen Elias
DOI: 10.1007/978-1-4419-5955-3_8
关键词:
摘要: In this chapter the preclinical considerations for antibody target discovery, validation, and in vitro vivo pharmacology will be discussed. A deep understanding of both biology pathology disease is essential identification validation. This knowledge enables rationale design therapeutic attributes including mechanism action (MOA), specificity, potency, isotype subclass, affinity, half-life. Subsequently, consideration utilization appropriate animal models enable optimal translation to clinic assist clinical trial design. Additionally, successful HER2 CD20 drug therapeutics presented as case studies.
springer.com
sci-hub.st 参考文章(171)
D. R. Anderson, A. Grillo-López, C. Varns, K. S. Chambers, N. Hanna, TARGETED ANTI-CANCER THERAPY USING RITUXIMAB, A CHIMAERIC ANTI-CD20 ANTIBODY (IDEC-C2B8) IN THE TREATMENT OF NON-HODGKIN'S B-CELL LYMPHOMA Biochemical Society Transactions. ,vol. 25, pp. 705- 708 ,(1997) , 10.1042/BST0250705
H.H Fiebig, A Maier, A.M Burger, Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. European Journal of Cancer. ,vol. 40, pp. 802- 820 ,(2004) , 10.1016/J.EJCA.2004.01.009
ME Reff, K Carner, KS Chambers, PC Chinn, JE Leonard, R Raab, RA Newman, N Hanna, DR Anderson, Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 Blood. ,vol. 83, pp. 435- 445 ,(1994) , 10.1182/BLOOD.V83.2.435.435
Suzanne A. Eccles, Models for Evaluation of Targeted Therapies of Metastatic Disease Humana Press. pp. 293- 319 ,(2002) , 10.1007/978-1-59259-100-8_17
Ronald Simon, Applications of Tissue Microarray Technology Methods in Molecular Biology. ,vol. 664, pp. 1- 16 ,(2010) , 10.1007/978-1-60761-806-5_1
J C Sarup, H M Shepard, B M Fendly, M T Lipari, K L King, A Ullrich, R M Johnson, M A Napier, Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth regulation. ,vol. 1, pp. 72- 82 ,(1991)
Daming Shan, Jeffrey A. Ledbetter, Oliver W. Press, Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies Blood. ,vol. 91, pp. 1644- 1652 ,(1998) , 10.1182/BLOOD.V91.5.1644
Kenneth R. Chien, Myocyte survival pathways and cardiomyopathy: implications for trastuzumab cardiotoxicity. Seminars in Oncology. ,vol. 27, pp. 9- 14 ,(2000)
L.R. Kelland, “Of mice and men”: values and liabilities of the athymic nude mouse model in anticancer drug development European Journal of Cancer. ,vol. 40, pp. 827- 836 ,(2004) , 10.1016/J.EJCA.2003.11.028
Stephen M. Hewitt, Tissue Microarrays as a Tool in the Discovery and Validation of Tumor Markers Methods of Molecular Biology. ,vol. 520, pp. 151- 161 ,(2009) , 10.1007/978-1-60327-811-9_11